Calvin Schmidt

Data scientist, synthetic biologist. Talk to me if you want to know more about or be better connected with the synthetic biology industry!

[Calvin Schmidt @calvinsynbio]

Want to be notified when the synthetic biology investing guide comes out? Sign up here and also get a tool for tracking public synthetic biology companies: https://t.co/fD0G58Axku
💉 #synbio #ginkgo $DNA 🧪
26/n

[Stephanie Schmidt, PhD @stephanie_sci]

I'm excited to share our recent publication in JCO Clinical Cancer Informatics on a flexible approach for integrating data across measurement platforms. @MDAndersonNews @JCOCCI_ASCO https://t.co/BUtvKdzvXB
(1/4)

[Calvin Schmidt @calvinsynbio]

Wonderful work not only integrating multiple data platforms to build better gene networks, but also providing a tool to explore these networks @stephanie_sci https://t.co/9dR0bdtxcr

[Jason Kelly @jrkelly]

biotech is growing the world.

[Peter Dykstra, PhD @Peter_Dykstra]

A nice way to kick off 2022! @matias_kaplan and I wrote a review in @NatureRevGenet diving into RNA engineering, RNA devices, and some exciting advances we've seen lately 🧬

[Breakout Ventures @breakout_vc]

We're excited to announce that we’ve closed our second fund, with $112.5M in commitments! We’ll continue to invest in Seed and Series A creative biosciences companies who are building bio-based solutions in #humanhealth and #sustainability.
https://t.co/D2bJMQyvO8

[Calvin Schmidt @calvinsynbio]

#synbio stocks were down 📉 6.2% last week to $175,572.4. Third down week in a row, as the broader market contracts.
https://t.co/KMwSPMVc4C

[Calvin Schmidt @calvinsynbio]

#synbio stocks were broadly down 📉 2.8% last week to $187,096.43.
https://t.co/KMwSPMDBd4

[Calvin Schmidt @calvinsynbio]

#synbio stocks were down 📉 2.3% last week to $192,522.96, thanks to some disappointing earnings reports.
https://t.co/KMwSPMDBd4

[Calvin Schmidt @calvinsynbio]

@matias_kaplan @BiochemPhD @pillar_vc @petribio @FounderLedBio RNAgang

[Calvin Schmidt @calvinsynbio]

#synbio stocks were up 📈 1.8% last week to $189,013.29. Another great week for infrastructure and tools companies.
https://t.co/KMwSPMVc4C

[Calvin Schmidt @calvinsynbio]

#synbio stocks were up 📈 5.6% last week to $185,695.88. Also an especially good week for companies recently targeted by Scorpion Capital. $DNA $BLI
https://t.co/KMwSPMDBd4

[Calvin Schmidt @calvinsynbio]

But at least provide real criticisms, and if you have an interest in an outcome, don't call it an "investigative report".
🧫 #synbio #ginkgo $DNA 🧪
15/n

[Calvin Schmidt @calvinsynbio]

Last week was pretty busy, but I had a chance over the weekend to review the Scorpion Capital report on $DNA.

My thoughts below.
🥼 #synbio #ginkgo $DNA 🧫
1/n

[Calvin Schmidt @calvinsynbio]

Ginkgo be indeed be overvalued, especially since it still has a valuation of over $20B
💉 #synbio #ginkgo $DNA 🥼
14/n